Silexion Therapeutics Corp., a clinical-stage biotechnology company specializing in RNA interference (RNAi) therapies for KRAS-driven cancers, has announced noteworthy preclinical results for its therapeutic candidate, SIL204. The data demonstrates SIL204's efficacy in inhibiting tumor proliferation across pancreatic, colorectal, and lung cancer cell lines, each harboring the KRAS G12D mutation. The study revealed a significant inhibition rate of approximately 90% in GP2D human colorectal cancer cells. SIL204 utilizes a lipid-conjugated delivery system to enhance the uptake and concentration of small interfering RNA (siRNA) within cells, showing potential for low-dose effectiveness. These findings suggest expanded therapeutic applications for SIL204, with Silexion planning further preclinical studies focused on lung cancer cell lines. The company's RNAi approach addresses a substantial unmet medical need in treating KRAS-driven cancers, which represent a large market with limited current treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.